Articles tagged with Cancer Medication
A promising new cancer drug developed by CSIRO's Cancer Therapeutics CRC has been licensed to US pharmaceutical company Merck in a $730 million deal. The drug targets the protein PRMT5, associated with various cancers, and may also provide disease-modifying treatment options for blood disorders.
Experts have issued a framework to guide difficult prioritization decisions among children in need of scarce life-saving chemotherapy treatment. The modified utilitarian model maximizes total benefit from available supply, considering factors like curability, prognosis, and drug importance.
A multi-center study identified distinct molecular and clinical features in diffuse glioma patients, shedding light on disease progression. The findings may lead to improved treatment outcomes by enabling precise prediction of tumor growth and response to therapy.
The study confirms the importance of sugar to cancer survival and provides essential new information for developing PI3K inhibitor drugs. The discovery creates a previously unidentified link between a cancer cell's form and shape and its metabolic capabilities.
Generic drugs are increasingly inaccessible due to pharmaceutical companies' strategies to delay market entry. These tactics include pay-for-delay deals, authorized generics, and product hopping, which can lead to higher prices for patients.
Researchers have discovered a molecule that blocks cancer stem cells' ability to survive and replicate. The compound, LF3, targets the Wnt signaling pathway and reduces tumor growth in living animals.
Biomedical engineers have created microscopic 'depots' to trap drugs inside cancer tumors, increasing their effectiveness. The technique uses nanocarriers and enzymes to release the drugs gradually, maximizing their impact on tumor growth.
Researchers create synthetic nanoparticles that can deliver miRNA-based therapies to late-stage liver cancer, inhibiting tumor growth and extending survival. The breakthrough addresses a major challenge in treating aggressive liver cancer, offering hope for patients with limited treatment options.
Researchers discovered a new cellular pathway where activation of TRIB3 gene causes tumour cell death by autophagy. The drug enhances anti-tumour effect of standard chemotherapies with low toxicity and high tolerability.
A team from the University of Leicester has published a detailed description of the protein Sam68 linked to many types of cancer. The high-resolution structure provides an opportunity for scientists to develop drugs targeting this protein.
Researchers found African-American children and adolescents with Hodgkin lymphoma had significantly lower overall survival rates at 25 years compared to their white and Hispanic counterparts. The study, published in Pediatric Blood & Cancer, analyzed data from over 7,800 patients across Florida and the US.
Researchers at UT Southwestern Medical Center have discovered that CDK4/6 inhibitors alter the metabolism of pancreatic cancer cells, revealing a biologic vulnerability. By targeting altered tumor metabolism with other drugs, it may be possible to positively impact cancer treatment.
The Damon Runyon Cancer Research Foundation awarded over $4.39M to 23 researchers conducting innovative cancer research, including four Breakthrough Scientists awards. These grants aim to support novel ideas and therapies in basic and translational cancer research.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have solved the atomic structure of a unique ubiquitin ligase complex, which plays a key role in modulating the immune system. The study reveals significant therapeutic potential for developing novel drug targets for cancer and inflammatory diseases.
The University of Chicago Medicine will receive a $5 million donation from the Hospira Foundation to create the Hospira Foundation Professorship in Oncology. This professorship will support research aimed at discovering new therapies and treatments for cancer.
A new study suggests that combining PARP inhibitors with c-MET inhibitors may improve treatment outcomes for patients with breast cancer and high c-MET expression levels.
Researchers identified DDA as a potent tumor suppressor metabolite derived from cholesterol and histamine cross-metabolization. Its discovery reveals a new metabolic pathway in mammals, potentially leading to the development of novel anticancer therapies.
Researchers at UNC-Chapel Hill have created a new cancer treatment that uses immune bubbles to deliver chemotherapy directly to tumors. This innovative approach reduces the need for high doses of chemotherapy, potentially leading to more effective treatment with fewer and milder side effects.
Researchers have discovered a way to light up a common cancer drug, allowing them to see where the chemo goes and how long it takes to get there. This breakthrough could lead to more personalized medicine and better understanding of how cells interact with drugs.
A recent study suggests new potential drug targets and combinations for treating breast cancer, including signaling proteins and proteins that regulate cell growth pathways. The research identifies candidate genes essential to cancer cell survival and validates a gene as a target for further study.
Changes in childhood cancer treatment and follow-up care have reduced deaths from late effects and extended lives of long-term survivors. Better screening guidelines and reduced radiation therapy have contributed to the decline in deaths.
Seven scientists with novel approaches to fighting cancer have been named recipients of the Damon Runyon-Rachleff Innovation Award. The grant funds cancer research by exceptionally creative thinkers with 'high-risk/high-reward' ideas, aiming to significantly impact cancer prevention, diagnosis, and treatment.
A recent US study found that minority and ethnic groups are being diagnosed with colorectal cancer at younger ages than non-Hispanic whites. The study reveals that these groups have twice the risk of developing the disease before age 50, with advanced stages at diagnosis.
Researchers from the Repurposing Drugs in Oncology project have found that diclofenac, a common painkiller, has significant anti-cancer properties. The study suggests that existing non-cancer drugs may represent a valuable source of novel therapies for cancer treatment.
A new study reveals that docetaxel retains effectiveness in patients with castration-resistant metastatic prostate cancer (mCRPC) treated with abiraterone. Following abiraterone, 40% of patients experienced a 50% reduction in prostate-specific antigen (PSA), demonstrating the activity of this drug sequencing.
Researchers found that auranofin reduces the survival rates of ovarian cancer cells with depleted BRCA1 levels, increasing their sensitivity to the drug. This suggests auranofin's potential as a clinical treatment for ovarian cancers with BRCA1 deficiency.
A recent study published in Cell Reports reveals that a group of protein kinases, specifically PKN2, play an essential role in congenital birth defects such as spina bifida. The researchers also found that these kinases may be potential cancer drug targets, particularly for pancreatic and breast cancers.
Researchers at The Wistar Institute used patient-derived xenograft (PDX) mouse models to test a combination of targeted therapies against relapsed melanoma. A MET inhibitor called capmatinib, when combined with BRAF and MEK inhibitors, showed significant tumor regression in all animals, suggesting a possible new mechanism of resistance.
Researchers at the University of Sheffield discovered that dasatinib can switch off signals in a protein implicated in Duchenne Muscular Dystrophy, leading to a 40% improvement in zebrafish with the condition. The drug has potential as a treatment for slowing muscle deterioration and improving symptoms in patients.
A recent study published in PLOS ONE found that statins increased overall survival among late-stage SCLC patients, while other medications showed no benefit. Radiotherapy was also identified as an independent predictor of survival.
A new injectable agent, LUM015, has been tested in a trial and found to identify cancerous tissue in human patients without adverse effects. The technology could significantly change the treatment of sarcoma by allowing surgeons to remove 100% of the tumor on the first attempt.
Researchers at the Children's Hospital of Philadelphia have identified a powerful new drug with unparalleled strength against forms of neuroblastoma that resist crizotinib. The study found that PF-06463922 showed more profound inhibition of ALK than crizotinib, leading to rapid and sustained regression in animal models.
A new study finds that Medicaid programs provide inadequate help for smoking cessation, with 10% of smokers receiving anti-smoking medication. States vary in their efforts to support smokers, with some providing more access than others.
The canSAR database has been upgraded with 3D protein structures and maps of cancer communication networks, allowing scientists to design new treatments more effectively. The updated database will enable researchers to identify key targets for future cancer drug discovery and develop innovative drugs more rapidly.
Researchers have discovered a triple therapy approach that could make treatment-resistant lung cancers susceptible to therapy. The combination of two experimental drugs and radiation therapy was found to be effective in mice with KRAS-related gene mutations.
A new study by Sylvester researchers describes the immune system's response to tumor development, highlighting the stimulator of interferon genes (STING) signaling pathway's potential suppression of colorectal cancer. Impaired STING responses may enable damaged cells to evade the immune system.
The new oral drug Palbociclib has shown promise in combating various types of cancer beyond breast cancer, including lymphoma, sarcoma, and teratoma. Early trials have demonstrated its effectiveness in slowing tumor growth and improving survival rates in patients with these conditions.
Researchers have identified NORAD, a long noncoding RNA, as crucial in maintaining proper chromosome numbers. Absence of NORAD leads to genomic instability and cells losing or gaining whole chromosomes.
Researchers discovered a novel mechanism of resistance and re-sensitization to first-generation ALK inhibitors in a patient with metastatic non-small-cell lung cancer. The study highlights the importance of repeat biopsies and molecular profiling to uncover novel resistance mechanisms.
Researchers have developed a computer model that applies social network analysis techniques to identify new ways of treating cancer. The model maps the interactions between cancer-causing proteins, predicting which ones will be most effectively targeted with drugs.
A study found that NSAIDs and opiates had no significant difference in pain scores, but NSAID use was associated with more rescue medication. Smaller chest tubes reduced pain, but efficacy has not been proven.
Mutations in follicular lymphoma have revealed new molecular targets for potential treatments, according to researchers at Queen Mary University of London. The mutations identified allow tumours to evade normal restrictions on growth, making existing therapies less effective.
A new system, TCRN, facilitates data and biospecimen sharing among cancer centers to speed up cancer research findings. This federated network uses advanced text processing technology to promote translational research across all cancer centers.
Researchers have found a class of drugs, histone deacetylase inhibitors, can eliminate kidney toxicity caused by cisplatin, a widely used chemotherapy agent. The combination therapy shows promise in reducing inflammation and cell death in the kidneys.
New research reveals that current genome analysis approaches miss detecting complex cancer mutations in well-known genes that could be targeted by existing drugs. The developed software tool, Pindel-C, identifies a large number of such events in critical cancer genes.
Researchers have found that tumors driven by IDH1 mutations are vulnerable to depletion of metabolite NAD+, which supports the development of new treatments. Inhibiting NAD+ levels can induce the death of IDH1-mutant tumor cells and inhibit tumor growth in animal models.
Researchers at VCU Massey Cancer Center describe how p53 gene mutations activate mTORC1, leading to abnormal cell proliferation. The study identifies a potential target for existing drug pemetrexed, which may have greater clinical utility against cancers with p53 dysfunction.
A new study found that experimental drugs changing energy supply in cells can halt tumor growth and extend survival in mice with cancers linked to IDH1 gene mutations. The research team discovered that cancer cells with low levels of a critical metabolic chemical, NAD, are more susceptible to these drugs.
The authors propose that lethal drugs' physical consequences should be listed as immediate cause of death and underlying condition as preceding antecedent cause. Harmonization with vital statistics registrars is crucial for consistency across provinces and territories.
A clinical trial found that anastrozole is as effective as tamoxifen in treating ductal carcinoma in situ (DCIS), a very early form of breast cancer. Anastrozole offers a new treatment option for post-menopausal women with fewer side effects, such as womb and ovarian cancers.
Researchers found similar outcomes for disease recurrence between women taking anastrozole and those taking tamoxifen, but noted significant differences in side effects. Women on anastrozole had fewer endometrial and ovarian cancers, while those on tamoxifen experienced more major thromboembolic events.
A study of postmenopausal women with DCIS found that anastrozole and tamoxifen caused different symptom profiles. Hot flashes were more common in the tamoxifen group, while musculoskeletal complaints and vaginal problems were more prevalent in those receiving anastrozole.
A single dose of psilocybin significantly decreases anxiety and depression in cancer patients, with positive effects lasting up to 6 months. The study suggests that psilocybin may be a sufficient treatment for mood disturbances in cancer patients.
Scientists at Princess Margaret Cancer Centre discovered that blocking the master regulator of bone renewal, RANKL, stops osteosarcoma. The findings provide a strong rationale for using this drug to develop targeted therapy for patients.
Researchers at Oregon State University have developed a three-drug delivery system that targets cancer cells in the lymph nodes, reducing toxicity and resistance. The technology has shown success in laboratory animals and holds potential for treating various types of cancer that spread through the lymphatic system.
A gold standard data record has been established to improve cancer genome analysis and detect somatic mutations reliably. The record, obtained from interlaboratory testing, provides a basis for laboratories to evaluate their bioinformatic methods and thresholds for detecting specific mutations.
A study of over 21,000 women found that only 1 in 6 with increased breast cancer risk take preventive medication, despite being eligible for clinical trials. Most women who started the medication continued taking it for at least a year, but usage declined over time.
Patients who discontinued ibrutinib or idelalisib due to side effects experienced durable responses after switching to another kinase inhibitor, with a 50% objective response rate and 11.9-month median progression-free survival.
A phase I/II clinical trial found that acalabrutinib promotes high response rates and durable results in patients with relapsed chronic lymphocytic leukemia while producing minimal side effects. The drug's selective blockade of the BTK pathway may offer improved tolerability compared to other treatments.
Researchers have developed a novel method to reposition an FDA-approved anti-cancer compound for targeting liver cancer tumors. The 'triple attack' technique uses nanobubbles filled with the drug to specifically target cancer cells, minimizing harm to healthy tissue.